Ipilimumab

A number of presentations during this year’s ASCO20 Virtual Scientific Program featured data on the efficacy and safety of immunotherapy combinations for the treatment of metastatic non-small cell lung cancer.

In this video, Upal Basu Roy, PhD, MPH, vice president of research at LUNGevity Foundation, spoke with Healio about three important presentations in non-small cell cancer from this year’s ASCO annual meeting.

Multisite stereotactic body radiotherapy, or SBRT, in combination with concurrent ipilimumab and nivolumab was well-tolerated in patients with stage 4 non-small cell lung cancer, according to findings from the COSINR study presented at the virtual ASCO Annual Meeting.

Patients with advanced non-small cell lung cancer who received nivolumab and ipilimumab demonstrated continued durable and long-term overall survival benefits compared with chemotherapy, according to data with 3-year minimum follow-up from the CheckMate 227 part 1 trial presented at the virtual ASCO Annual Meeting.

The first two doses of nivolumab with ipilimumab appeared to drive efficacy and toxicity of the combination among certain patients with melanoma, according to phase 2 study results presented during the ASCO20 Virtual Scientific Program.

First-line nivolumab with ipilimumab and a limited chemotherapy course significantly improved OS among patients with metastatic non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity among patients with advanced melanoma who failed prior treatment, according to phase 2 study results presented during the ASCO20 Virtual Scientific Program.

Nivolumab plus ipilimumab continued to provide long-term OS benefits compared with chemotherapy as initial treatment for advanced non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

A combination of nivolumab and ipilimumab conferred durable partial responses among certain patients with treatment-refractory advanced renal cell carcinoma, according to phase 2 study results presented at the virtual ASCO Annual Meeting.

The FDA expanded the approval of nivolumab plus ipilimumab for treatment of lung cancer, according to the agents’ manufacturer.